Production (Stage)
Allarity Therapeutics, Inc.
ALLR
$1.03
-$0.035-3.29%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 11.01M | 11.44M | 8.23M | 9.12M | 9.86M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -803.00K | -803.00K | -805.00K | -805.00K | -800.00K |
| Total Operating Expenses | 16.33M | 17.54M | 15.10M | 16.92M | 17.70M |
| Operating Income | -16.33M | -17.54M | -15.10M | -16.92M | -17.70M |
| Income Before Tax | -23.78M | -24.90M | -19.08M | -11.56M | -12.31M |
| Income Tax Expenses | -377.00K | -381.00K | -298.00K | 79.00K | 79.00K |
| Earnings from Continuing Operations | -23.40 | -24.52 | -18.78 | -11.64 | -12.39 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -23.40M | -24.52M | -18.78M | -11.64M | -12.39M |
| EBIT | -16.33M | -17.54M | -15.10M | -16.92M | -17.70M |
| EBITDA | -16.32M | -17.53M | -15.08M | -16.90M | -17.67M |
| EPS Basic | -13.02 | -12.78 | -11.05 | -3.34 | -- |
| Normalized Basic EPS | -4.17 | -4.01 | -2.94 | -2.04 | -- |
| EPS Diluted | -13.02 | -12.78 | -11.05 | -3.34 | -- |
| Normalized Diluted EPS | -4.17 | -4.01 | -2.94 | -2.04 | -- |
| Average Basic Shares Outstanding | 17.55M | 6.41M | 2.08M | 499.30K | -- |
| Average Diluted Shares Outstanding | 17.55M | 6.41M | 2.08M | 499.30K | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |